Literature DB >> 31486941

Plasticity of the HEK-293 cells, related to the culture media, as platform to produce a subunit vaccine against classical swine fever virus.

Elianet Lorenzo1, Lidice Méndez1, Elsa Rodríguez1, Nemecio Gonzalez2, Gleysin Cabrera3, Carlos Pérez2, Rafael Pimentel2, Yusmel Sordo1, Maria P Molto1, Talia Sardina1, Alina Rodríguez-Mallon1, Mario P Estrada4.   

Abstract

Classical swine fever (CSF) is a contagious disease that causes a high mortality to domestic and wild pigs. Its causative agent is an enveloped Pestivirus named Classical Swine Fever Virus (CSFV). Due to the huge economic affectations produced by this disease to porcine industry, several vaccines have been developed using principally the CSFV E2 glycoprotein. Recently, a subunit vaccine based on this structural protein of the CSFV fused to the porcine CD154 molecule as immunomodulator named E2-CD154 was assayed by us. This chimeric protein was produced in the Human Embryonic Kidney (HEK-293) cell line. In this work, the growth and the expression profiles of HEK-293 E2-CD154 cells in four commercially available culture media were studied. The oligosaccharide structures in the N-glycosylation patterns of the E2-CD154 protein produced by this cell line in 10 L fermenters with two different culture media were also analyzed. In addition, the neutralizing antibody response generated in mice vaccinated with these antigens was assayed. Our results suggest that the culture media CDM4HEK293 and SFM4HEK293 which are recommended for HEK-293 growth are the best choice to growth the cell clone expressing the E2-CD154 protein. The glycosylation pattern and the neutralizing antibody response generated by the E2-CD154 protein were independent of the culture medium used which demonstrates the high reproducibility and consistency among protein batches produced by HEK-293 cells even in different culture conditions.

Entities:  

Keywords:  Culture media; Glycoprotein E2-CD154; Growth profiles; HEK-293 cells; N-Glycosylation

Year:  2019        PMID: 31486941      PMCID: PMC6728104          DOI: 10.1186/s13568-019-0864-8

Source DB:  PubMed          Journal:  AMB Express        ISSN: 2191-0855            Impact factor:   3.298


  27 in total

1.  Efficacy and stability of a subunit vaccine based on glycoprotein E2 of classical swine fever virus.

Authors:  A Bouma; A J de Smit; E P de Kluijver; C Terpstra; R J Moormann
Journal:  Vet Microbiol       Date:  1999-04-01       Impact factor: 3.293

2.  Classical swine fever (CSF) marker vaccine. Trial I. Challenge studies in weaner pigs.

Authors:  A Uttenthal; M F Le Potier; L Romero; G M De Mia; G Floegel-Niesmann
Journal:  Vet Microbiol       Date:  2001-11-08       Impact factor: 3.293

3.  A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice.

Authors:  R Xiang; F J Primus; J M Ruehlmann; A G Niethammer; S Silletti; H N Lode; C S Dolman; S D Gillies; R A Reisfeld
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

4.  The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40.

Authors:  V Henn; S Steinbach; K Büchner; P Presek; R A Kroczek
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

Review 5.  Introduction to classical swine fever: virus, disease and control policy.

Authors:  V Moennig
Journal:  Vet Microbiol       Date:  2000-04-13       Impact factor: 3.293

6.  [Vaccination of weaner pigs against classical swine fever with the subunit vaccine "Porcilis Pesti": influence of different immunization plans on excretion and transmission of challenge virus].

Authors:  Ute Ziegler; Volker Kaden
Journal:  Berl Munch Tierarztl Wochenschr       Date:  2002 Jul-Aug       Impact factor: 0.328

7.  Live attenuated pseudorabies virus expressing envelope glycoprotein E1 of hog cholera virus protects swine against both pseudorabies and hog cholera.

Authors:  M van Zijl; G Wensvoort; E de Kluyver; M Hulst; H van der Gulden; A Gielkens; A Berns; R Moormann
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

8.  Classical swine fever virus E2 glycoprotein antigen produced in adenovirally transduced PK-15 cells confers complete protection in pigs upon viral challenge.

Authors:  Oliberto Sánchez; Maritza Barrera; María P Rodríguez; María T Frías; Nancy E Figueroa; Paula Naranjo; Raquel Montesino; Omar Farnos; Sara Castell; Alina Venereo; Llilianne Ganges; Carlos Borroto; Jorge R Toledo
Journal:  Vaccine       Date:  2007-11-26       Impact factor: 3.641

9.  Effect of N-glycosylation inhibition on the synthesis and processing of classical swine fever virus glycoproteins.

Authors:  Jolanta Tyborowska; Ewa Zdunek; Bogusław Szewczyk
Journal:  Acta Biochim Pol       Date:  2007-12-17       Impact factor: 2.149

10.  Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells.

Authors:  Martin Loignon; Sylvie Perret; John Kelly; Denise Boulais; Brian Cass; Louis Bisson; Fatemeh Afkhamizarreh; Yves Durocher
Journal:  BMC Biotechnol       Date:  2008-08-27       Impact factor: 2.563

View more
  4 in total

1.  Designing a novel E2-IFN-γ fusion protein against CSFV by immunoinformatics and structural vaccinology approaches.

Authors:  Yanmin Zhang; Weijian Zhang; Jun Cheng; Xuping Liu; Shiwei Miao; Wen-Song Tan; Liang Zhao
Journal:  Appl Microbiol Biotechnol       Date:  2022-05-07       Impact factor: 4.813

Review 2.  Research Progress and Challenges in Vaccine Development against Classical Swine Fever Virus.

Authors:  Qiang Wei; Yunchao Liu; Gaiping Zhang
Journal:  Viruses       Date:  2021-03-10       Impact factor: 5.048

Review 3.  Future perspectives on swine viral vaccines: where are we headed?

Authors:  Tanja Opriessnig; Ashley A Mattei; Anbu K Karuppannan; Patrick G Halbur
Journal:  Porcine Health Manag       Date:  2021-01-04

4.  Establishing functional lentiviral vector production in a stirred bioreactor for CAR-T cell therapy.

Authors:  Qu-Lai Tang; Li-Xing Gu; Yao Xu; Xing-Hua Liao; Yong Zhou; Tong-Cun Zhang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.